Immatics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

ImmaticsDer Gewinn des Unternehmens wird voraussichtlich um 8.1% pro Jahr sinken, während der Jahresumsatz voraussichtlich um 13.2% pro Jahr wachsen wird. Der Gewinn pro Aktie wird voraussichtlich um 0.6% pro Jahr wachsen.

Wichtige Informationen

-13.4%

Wachstumsrate der Gewinne

-5.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.2%
Wachstumsrate der Einnahmen	10.0%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	16 Sep 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Apr 01

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?

Jan 18

Immatics reports Q3 results

Dec 02

Immatics (IMTX) Investor Presentation - Slideshow

Nov 13

Gewinn- und Umsatzwachstumsprognosen

NasdaqCM:IMTX - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	50	-157	-148	N/A	4
12/31/2025	56	-139	-112	N/A	6
12/31/2024	75	-92	-111	N/A	6
6/30/2024	71	-74	-45	-17	N/A
3/31/2024	74	-80	-26	9	N/A
12/31/2023	54	-97	-13	18	N/A
9/30/2023	76	-84	-117	-92	N/A
6/30/2023	85	-79	-113	-94	N/A
3/31/2023	80	-68	-40	-31	N/A
12/31/2022	173	38	94	100	N/A
9/30/2022	151	34	97	102	N/A
6/30/2022	142	28	113	119	N/A
3/31/2022	130	15	38	44	N/A
12/31/2021	35	-93	-90	-85	N/A
9/30/2021	28	-95	-86	-81	N/A
6/30/2021	30	-231	-133	-127	N/A
3/31/2021	32	-226	-97	-91	N/A
12/31/2020	31	-211	-88	-81	N/A
9/30/2020	26	-208	-38	-31	N/A
6/30/2020	23	-49	75	81	N/A
3/31/2020	22	-34	55	60	N/A
12/31/2019	18	-32	69	71	N/A
12/31/2018	4	-31	20	21	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: IMTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: IMTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: IMTX wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: IMTXDie Einnahmen des Unternehmens (13.2% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: IMTXDie Einnahmen des Unternehmens (19% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von IMTX in 3 Jahren voraussichtlich hoch sein wird

Immatics Zukünftiges Wachstum

Future Kriterienprüfungen 1/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 7.9% to US$17.50

Consensus estimates of losses per share improve by 10%

Price target increased by 8.2% to US$19.83

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$18.25

Consensus EPS estimates increase by 76%

Recent updates

Immatics N.V.'s (NASDAQ:IMTX) Price Is Out Of Tune With Revenues

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Price target decreased by 7.9% to US$17.50

Immatics N.V. Appoints Alise Reicin to Board of Directors

Immatics (NASDAQ:IMTX) Is In A Good Position To Deliver On Growth Plans

New major risk - Financial position

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus estimates of losses per share improve by 10%

New major risk - Revenue and earnings growth

Pinning Down Immatics N.V.'s (NASDAQ:IMTX) P/S Is Difficult Right Now

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS exceeds analyst expectations

Immatics N.V., Annual General Meeting, Jun 19, 2024

Immatics N.V. has completed a Follow-on Equity Offering in the amount of $175.175 million.

Immatics N.V. has filed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

New major risk - Financial position

Price target increased by 8.2% to US$19.83

Immatics N.V. Reports Interim Clinical Data from ACTengine IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRame in an Ongoing Phase 1 Trial

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Immatics N.V. Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine(R) IMA203 TCR-T Monotherapy

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V. Initiates Phase 1/2 Clinical Trial to Evaluate Promame TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

We're Hopeful That Immatics (NASDAQ:IMTX) Will Use Its Cash Wisely

Immatics N.V., Annual General Meeting, Jun 20, 2023

First quarter 2023 earnings released: €0.26 loss per share (vs €1.36 profit in 1Q 2022)

Investor sentiment improves as stock rises 42%

Investor sentiment improves as stock rises 22%

Consensus revenue estimates increase by 11%, EPS downgraded

Price target decreased by 8.8% to US$18.25

Full year 2022 earnings released: EPS: €0.56 (vs €1.48 loss in FY 2021)

Investor sentiment deteriorated over the past week

Consensus EPS estimates increase by 76%

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Immatics Reports Interim Clinical Data Update on Actengine(R) Ima203 Tcr-T Monotherapy Targeting Prame

Immatics launches $110M stock offering

Investor sentiment deteriorated over the past week

Immatics N.V. Presents Comprehensive Preclinical Data Set for Tcr Bispecific Candidate Ima402 Targeting Prame At European Society for Medical Oncology (Esmo) Congress 2022

Immatics N.V. Announces First Cancer Patient Treated with Second-Generation Actengine(R) Tcr-T Candidate Ima203cd8 Targeting Prame

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Investor sentiment improved over the past week

Cancer immunotherapy biotech Immatics up 18% on 4x normal volume

Price target decreased to US$20.00

First quarter 2022 earnings: EPS and revenues miss analyst expectations

Immatics N.V., Annual General Meeting, Jun 13, 2022

Immatics N.V. Announces First Patient Treated with Actengine® Ima203 Tcr-T in Combination with Checkpoint Inhibitor Opdivo® (Nivolumab) in Patients with Advanced Solid Tumors

Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors

Price target decreased to US$22.80

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Forecast to breakeven in 2022

Consensus forecasts updated

Here's Why We're Watching Immatics' (NASDAQ:IMTX) Cash Burn Situation

Analysts' Revenue Estimates For Immatics N.V. (NASDAQ:IMTX) Are Surging Higher

Consensus forecasts updated

Third quarter 2021 earnings released: €0.43 loss per share (vs €2.61 loss in 3Q 2020)

Second quarter 2021 earnings released: €0.38 loss per share (vs €18.08 loss in 2Q 2020)

Supervisory Director Christof Hettich has left the company

Supervisory Director Christof Hettich has left the company

Consensus forecasts updated

First quarter 2021 earnings released: €0.34 loss per share (vs €7.14 loss in 1Q 2020)

Immatics Presents Preclinical Proof-Of-Concept Data for TCR Bispecifics Program IMA402 Targeting PRAME

Full year 2020 earnings released: €4.77 loss per share (vs €0.95 loss in FY 2019)

Immatics N.V. (NASDAQ:IMTX) Analysts Are Pretty Bullish On The Stock After Recent Results

Immatics N.V., Annual General Meeting, Jun 17, 2021

Immatics Presents Data Update on Dose Escalation from Ongoing ACTengine® Cell Therapy Programs

New 90-day high: US$11.56

What Is The Ownership Structure Like For Immatics N.V. (NASDAQ:IMTX)?